Jefferies & Co Upgrades Noven Pharmaceuticals (NOVN) to Hold
More News related to NOVN
- After-Hours Movers 8/18: SPRD, CLZR, IPAS, LZB, KTCC, SIGM Higher; VTG, ADPI, ADI, LFT, GA, HPQ Lower
- S&P Announces Update to US Indices Liquidity Criteria; SIGM to Replace NOVN
- Caris Downgrades Noven Pharma (NOVN) to Neutral
- Ladenburg Thalmann Downgrades Noven Pharmaceuticals (NOVN) to Neutral
- Unusual 11 Mid-Day Movers 7/14: HITK, NOVN, NSU, IMMU Higher; SBGI, CPF, HNT, COBZ Lower
Jefferies & Co upgrades Noven Pharmaceuticals (Nasdaq: NOVN) from Underperform to Hold.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. (Noven) is a specialty pharmaceutical company engaged in the research, development, manufacturing, licensing, marketing and sale of prescription pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
